Novel Approaches in the Management of Mucormycosis.

IF 2.3 Q3 INFECTIOUS DISEASES Current Fungal Infection Reports Pub Date : 2023-05-08 DOI:10.1007/s12281-023-00463-3

Frederic Lamoth

{"title":"Novel Approaches in the Management of Mucormycosis.","authors":"Frederic Lamoth","doi":"10.1007/s12281-023-00463-3","DOIUrl":null,"url":null,"abstract":"Purpose of review: Invasive mucormycosis (IM), caused by fungi of the order Mucorales, is one of the deadliest fungal infection among hematologic cancer patients. Its incidence is also increasingly reported in immunocompetent individuals, notably with the COVID-19 pandemic. Therefore, there is an urgent need for novel diagnostic and therapeutic approaches of IM. This review discusses the current advances in this field.Recent findings: Early diagnosis of IM is crucial and can be improved by Mucorales-specific PCR and development of lateral-flow immunoassays for specific antigen detection. The spore coat proteins (CotH) are essential for virulence of the Mucorales and may represent a target for novel antifungal therapies. Adjuvant therapies boosting the immune response, such as interferon-γ, anti-PDR1 or fungal-specific chimeric antigen receptor (CAR) T-cells, are also considered.Summary: The most promising perspectives for improved management of IM consist of a multilayered approach targeting both the pathogen and the host immune system.","PeriodicalId":10813,"journal":{"name":"Current Fungal Infection Reports","volume":" ","pages":"1-10"},"PeriodicalIF":2.3000,"publicationDate":"2023-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10165581/pdf/","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Fungal Infection Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s12281-023-00463-3","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 1

Abstract

Purpose of review: Invasive mucormycosis (IM), caused by fungi of the order Mucorales, is one of the deadliest fungal infection among hematologic cancer patients. Its incidence is also increasingly reported in immunocompetent individuals, notably with the COVID-19 pandemic. Therefore, there is an urgent need for novel diagnostic and therapeutic approaches of IM. This review discusses the current advances in this field.

Recent findings: Early diagnosis of IM is crucial and can be improved by Mucorales-specific PCR and development of lateral-flow immunoassays for specific antigen detection. The spore coat proteins (CotH) are essential for virulence of the Mucorales and may represent a target for novel antifungal therapies. Adjuvant therapies boosting the immune response, such as interferon-γ, anti-PDR1 or fungal-specific chimeric antigen receptor (CAR) T-cells, are also considered.

Summary: The most promising perspectives for improved management of IM consist of a multilayered approach targeting both the pathogen and the host immune system.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

毛霉菌病治疗的新方法。

综述目的：侵袭性毛霉菌病（IM）是由毛霉菌目真菌引起的，是癌症患者中最致命的真菌感染之一。其发病率也越来越多地报告在具有免疫能力的个体中，尤其是在新冠肺炎大流行中。因此，迫切需要新的IM诊断和治疗方法。这篇综述讨论了这一领域的最新进展。最近的发现：IM的早期诊断至关重要，可以通过毛霉素特异性PCR和开发用于特异性抗原检测的侧流免疫分析来改善。孢子外壳蛋白（CotH）对毛霉素的毒力至关重要，可能是新型抗真菌疗法的靶点。还考虑了增强免疫反应的辅助疗法，如干扰素-γ、抗PDR1或真菌特异性嵌合抗原受体（CAR）T细胞。摘要：改善IM管理的最有前景的前景包括针对病原体和宿主免疫系统的多层次方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current Fungal Infection Reports INFECTIOUS DISEASES-

CiteScore

3.10

自引率

7.10%

发文量

期刊介绍： This journal intends to provide clear, insightful, balanced contributions that review the most important, recently published clinical findings related to the diagnosis, treatment, management, and prevention of fungal infections. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as advances in diagnosis, current and emerging management approaches, and genomics and pathogenesis. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. Commentaries from well-known figures in the field are also provided, and an international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research.